Summary
Amgen Inc. (AMGN) filed an 8-K on July 26, 2007, to report its unaudited financial results for the second quarter and the first half of 2007. The filing primarily detailed the company's use of non-GAAP financial measures to provide investors with a clearer view of its performance, excluding certain significant items. These adjustments are crucial for understanding the company's operational performance by isolating the impact of stock option expensing (SFAS No. 123R), merger and acquisition-related costs (including those from Avidia, Abgenix, Tularik, and Immunex), manufacturing asset write-offs, impairment charges, tax benefits from resolving transfer pricing issues, and convertible note expenses. Amgen believes these non-GAAP measures facilitate better period-over-period comparisons and offer insights into the underlying profitability of its operations, particularly concerning its intellectual property.
Key Highlights
- 1Amgen announced its unaudited financial results for the three and six months ended June 30, 2007.
- 2The company is presenting non-GAAP financial measures to offer a more comparable view of its performance.
- 3Adjustments exclude the impact of expensing stock options under SFAS No. 123R.
- 4Significant merger and acquisition-related costs from recent acquisitions (Avidia, Abgenix, Tularik, Immunex) are excluded in non-GAAP reporting.
- 5The filing details exclusions for manufacturing asset write-offs, impairment charges, and a tax benefit from transfer pricing resolutions.
- 6Non-GAAP measures also exclude convertible note expenses related to bondholder put options.
- 7Amgen believes these non-GAAP measures provide valuable supplementary information to investors for analysis.